Aura Biosciences Starts Phase 1 Study Evaluating Belzupacap Sarotalocan in Bladder Cancer

  Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the first patient has been dosed in a Phase 1 study evaluating belzupacap sarotalocan, the Company’s first VDC product candidate, for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).

https://www.biospace.com/article/releases/aura-biosciences-announces-first-patient-dosed-in-phase-1-study-evaluating-belzupacap-sarotalocan-au-011-for-the-treatment-of-non-muscle-invasive-bladder-cancer/